Beta Bionics, Inc.
BBNX
Positions held
Your positionsBBNX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Beta Bionics, Inc. is positioned in the growing medical devices sector, which is expected to expand due to increasing healthcare needs and technological advancements.
- In Q2 2026, Beta Bionics reported a revenue increase of 16% compared to the previous quarter, reaching $32 million.
- The company has a current ratio of 8.88, indicating strong liquidity and the ability to cover short-term liabilities.
- The company faces significant challenges with a negative profit margin of -61.31%, which raises concerns about its financial sustainability.
- In 2025, Beta Bionics reported a net income loss of $73.2 million, reflecting ongoing operational difficulties.
- The operating margin for Q2 2026 was -79.9%, indicating persistent inefficiencies in managing operational costs.
Fundamentals
| Market cap | $940.28M | Enterprise value | $610.19M | Trailing P/E | — | Forward P/E | -7.50 |
| PEG | — | Price / book | 3.06 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 37.8% | Earnings growth | — | Gross margin | 58.3% | Operating margin | -79.9% |
| Profit margin | -61.3% | ROE | -26.2% | ROA | -16.7% | Debt / equity | 0.03 |
| Current ratio | 8.88 | Free cash flow | -$40.29M | Analyst recommendation | buy | Mean target | $23.80 |
| 52w high | $32.71 | 52w low | $8.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $32.0M | $27.6M | $32.1M | $27.3M | $23.2M | — |
| Op margin | -79.9% | -87.9% | -50.2% | -62.5% | -85.5% | — |
| Net income | -$23.4M | -$21.9M | -$13.5M | -$14.2M | -$16.9M | — |
| Gross margin | 59.0% | 59.5% | 59.0% | 55.5% | 53.8% | — |
| Gross profit | $18.9M | $16.4M | $18.9M | $15.1M | $12.5M | — |
| Operating income | -$25.6M | -$24.3M | -$16.1M | -$17.0M | -$19.9M | — |
- Revenue +16% vs prior quarter ($32M vs $28M).
- Gross margin 59% (was 59.5% prior quarter).
- Operating margin expanded to -79.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $100M | $65.1M | $12.0M | $0.2M |
| Op margin | -71.5% | -69.5% | -298.9% | -36784.4% |
| Net income | -$73.2M | -$54.8M | -$44.1M | -$64.8M |
| Gross margin | 55.4% | 55.1% | 52.6% | 100.0% |
| Gross profit | $55.5M | $35.9M | $6.3M | $0.2M |
| Operating income | -$71.7M | -$45.3M | -$35.9M | -$65.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Beta Bionics (BBNX) Stock Fair Value Rises After Mint Clearance And Analyst Target Changes
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Barclays Initiates Beta Bionics at Overweight With $30 Price Target
2026-09-29 · Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
2026-09-29 · Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
2026-09-24 · Truist Raises Price Target on Beta Bionics to $28 From $23, Keeps Buy Rating
2026-09-23 · Wells Fargo Initiates Beta Bionics at Overweight With $28 Price Target
2026-09-22 · Sector Update: Healthcare Stocks Rise Late Afternoon
2026-09-22 · Sector Update: Healthcare
2026-09-22 · Update: Beta Bionics, Senseonics to Integrate Diabetes Devices; Shares Rise
2026-09-22 · Beta Bionics, Senseonics Partner to Integrate Diabetes Devices
2026-09-22 · Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
Price (daily)
Full chart · RSI · MACD · patterns